Please ensure Javascript is enabled for purposes of website accessibility

Can Amwell Catch Up to Teladoc Health?

By Cory Renauer - May 16, 2021 at 9:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

See how the smaller telehealth provider's first-quarter performance stacked up against the industry leader.

Do you enjoy carving hours out of your busy day to get a few minutes of face time with a doctor? If you don't, you're not alone. If we've learned anything over the past year and a half, it's that Americans are hungry for medical services that can be provided without the rest of the doctor's office experience. 

Last September, Amwell (AMWL 4.71%) attracted a whopping $742 million in a highly successful IPO because it seemed like a strong contender in the race to dominate a still-fragmented market led by Teladoc Health (TDOC 6.72%)

Telehealth doctor at work.

Image source: Getty Images.

The adoption of long-distance medical services hasn't slowed down since Amwell's stock market debut. Unfortunately for Amwell, the number of well-funded companies trying to tackle the market leader is on the rise too.

Shares of Amwell have lost nearly half their value since the company's IPO because investors are worried it won't be able to carve out a large share of the space currently led by Teladoc Health. Now that both companies have reported first-quarter earnings, we can see if Amwell's gaining on the leader or falling further behind.

Subscriber growth

When it comes to overall usage, Amwell's still far behind Teladoc, but it's gaining fast. In the first quarter of 2021, Amwell hosted 1.6 million visits on its telehealth platform. That was a 120% gain over the previous year period, but still just half as many as Teladoc Health. During the same period, the industry leader facilitated 3.2 million visits, which was 56% more than a year earlier.

Both companies want reliable cash flows that come from a growing base of subscribers who eventually pay for add-on services. To this end, Teladoc is clearly in the lead with subscription access fees that more than tripled year over year to reach $388 million during the first quarter. Total subscription fees collected by Amwell in the first quarter grew just 13% year over year to $24.6 million.

Health signals

America's healthcare system is heavily geared toward providing acute care even though chronic conditions like diabetes, asthma, and hypertension are responsible for the vast majority of total healthcare expenses. Teladoc's acquisition of applied health signals specialist, Livongo last year positioned the company to become America's chronic care specialist, and it's driving subscription revenue.

In the first quarter, subscriptions contributed 43% of total revenue to Amwell's top line. That was a significant improvement from 40% in the previous year period, but it's miles behind Teladoc. In the first quarter, subscription fees worked out to around 86% of total revenue for Teladoc Health.

In the margins

Fees paid out to providers and other costs of revenue worked out to $146 million, about 32% of Teladoc's total revenue in the first three months of 2021. For Amwell, costs of revenue in the first quarter worked out to $36 million, or about 62% of total revenue.

Both companies are still reporting significant net losses, but just one of them is marching toward profitability. Once you adjust for non-cash expenses unlikely to be repeated, Teladoc Health reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached $57 million in the first quarter. On the same yardstick, Amwell lost $26 million during the first three months of 2021.

It doesn't look good

Thanks to a successful IPO last year, Amwell finished March with $996 million in cash on its balance sheet. This is a nice cushion, but it isn't enough to win a race to the bottom with a growing list of well-funded competitors in the telehealth space.

Teladoc Health had 51.5 million paying subscribers at the end of March, but it might not be Amwell's largest competitor for much longer. One of America's largest healthcare benefits managers, Cigna (NYSE: CI) recently acquired MDLive. This was already one of the largest privately held providers of telehealth services before Cigna came along. Now it has contracts that cover over 60 million lives.

So far, Amwell hasn't shown strong signs it can differentiate itself in the increasingly crowded market for telehealth services. Until we see subscription growth and margin improvements that suggest Amwell can rise to the top of this space, investors should keep looking for better healthcare stocks to buy.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

American Well Corporation Stock Quote
American Well Corporation
$5.11 (4.71%) $0.23
Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$37.79 (6.72%) $2.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.